• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study.Claudin-7、程序性死亡受体1(PDL-1)、第10号染色体缺失的磷酸酶及张力蛋白同源物(PTEN)、原癌基因c-Kit、肝细胞生长因子受体(c-Met)、原癌基因c-Myc、间变性淋巴瘤激酶(ALK)、细胞角蛋白5/6(CK5/6)、细胞角蛋白17(CK17)、抑癌基因p53、表皮生长因子受体(EGFR)、细胞增殖相关核抗原(Ki67)、抑癌基因p63在三阴性乳腺癌中的表达及临床意义——一项单中心前瞻性观察性研究
In Vivo. 2018 Mar-Apr;32(2):303-311. doi: 10.21873/invivo.11238.
2
c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.基底样和非基底样三阴性乳腺癌中c-Met和ERβ的表达差异
Tumour Biol. 2016 Aug;37(8):11385-95. doi: 10.1007/s13277-016-5010-5. Epub 2016 Mar 11.
3
[Expression of CK5/6 and CK17 and its correlation with prognosis of triple-negative breast cancer patients].[CK5/6和CK17的表达及其与三阴性乳腺癌患者预后的相关性]
Zhonghua Zhong Liu Za Zhi. 2008 Aug;30(8):610-4.
4
Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype.三阴性表型乳腺癌患者中基底细胞角蛋白表达与免疫组化及临床特征的关系
Tumori. 2009 Jan-Feb;95(1):53-62. doi: 10.1177/030089160909500110.
5
Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer.细胞角蛋白 5/6、c-Met 表达和 PTEN 缺失与三阴性乳腺癌的预后相关。
Med Oncol. 2014 Jan;31(1):801. doi: 10.1007/s12032-013-0801-7. Epub 2013 Dec 11.
6
Is vimentin a potential prognostic factor for patients with triple-negative breast cancer?波形蛋白是否是三阴性乳腺癌患者的潜在预后因素?
J Cancer Res Clin Oncol. 2020 Aug;146(8):2109-2116. doi: 10.1007/s00432-020-03210-0. Epub 2020 Apr 7.
7
Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.使用组合生物标志物对三阴性乳腺癌患者的预后进行分层
PLoS One. 2016 Mar 1;11(3):e0149661. doi: 10.1371/journal.pone.0149661. eCollection 2016.
8
Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.细胞角蛋白5/6、雄激素受体和p53的免疫组化共表达状态作为三阴性乳腺癌辅助化疗的预后因素
Med Mol Morphol. 2016 Mar;49(1):11-21. doi: 10.1007/s00795-015-0109-0. Epub 2015 May 26.
9
Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma.三阴性乳腺浸润性导管癌患者中p53表达与预后不良的相关性
Medicine (Baltimore). 2019 May;98(18):e15449. doi: 10.1097/MD.0000000000015449.
10
Potential prognostic tumor biomarkers in triple-negative breast carcinoma.三阴性乳腺癌中潜在的预后肿瘤生物标志物
Beijing Da Xue Xue Bao Yi Xue Ban. 2012 Oct 18;44(5):666-72.

引用本文的文献

1
Predicting recurrence of non-muscle invasive bladder urothelial carcinoma: predictive value of the optimal cut-off value of Ki67.预测非肌层浸润性膀胱尿路上皮癌的复发:Ki67最佳临界值的预测价值
Front Oncol. 2025 Jan 16;14:1522009. doi: 10.3389/fonc.2024.1522009. eCollection 2024.
2
Immunohistochemical Expression of PD-L1 and CTLA-4 in Triple Negative Breast Cancer and Their Prognostic Associations.PD-L1和CTLA-4在三阴性乳腺癌中的免疫组化表达及其预后相关性
Asian Pac J Cancer Prev. 2025 Jan 1;26(1):319-326. doi: 10.31557/APJCP.2025.26.1.319.
3
Effect of Androgen receptors in Triple-Negative Breast Cancer Given Neoadjuvant Therapy: A Systematic Review and Meta-Analysis.雄激素受体在接受新辅助治疗的三阴性乳腺癌中的作用:一项系统评价和荟萃分析
Asian Pac J Cancer Prev. 2024 Dec 1;25(12):4115-4122. doi: 10.31557/APJCP.2024.25.12.4115.
4
Tissue Microarray Immunohistochemical Staining for Androgen Receptor in Breast Cancer in a Ghanaian Cohort.在加纳队列中进行乳腺癌组织微阵列免疫组织化学染色检测雄激素受体。
Ann Afr Med. 2024 Jul 1;23(3):452-458. doi: 10.4103/aam.aam_83_23. Epub 2024 Apr 5.
5
Programmed Death-Ligand (PD-L1), Epidermal Growth Factor (EGF), Relaxin, and Matrix Metalloproteinase-3 (MMP3): Potential Biomarkers of Malignancy in Canine Mammary Neoplasia.程序性死亡配体(PD-L1)、表皮生长因子(EGF)、松弛素和基质金属蛋白酶-3(MMP3):犬乳腺肿瘤恶性肿瘤的潜在生物标志物。
Int J Mol Sci. 2024 Jan 18;25(2):1170. doi: 10.3390/ijms25021170.
6
MYCL promotes the progression of triple‑negative breast cancer by activating the JAK/STAT3 pathway.MYCL 通过激活 JAK/STAT3 通路促进三阴性乳腺癌的进展。
Oncol Rep. 2022 Nov;48(5). doi: 10.3892/or.2022.8418. Epub 2022 Sep 30.
7
Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker.三阴性乳腺癌患者血清中表皮生长因子受体(EGFR)的表达:该生物标志物的预后价值
Ecancermedicalscience. 2022 Jul 20;16:1431. doi: 10.3332/ecancer.2022.1431. eCollection 2022.
8
c-Kit Induces Migration of Triple-Negative Breast Cancer Cells and Is a Promising Target for Tyrosine Kinase Inhibitor Treatment.c-Kit 诱导三阴性乳腺癌细胞迁移,是酪氨酸激酶抑制剂治疗的有前途的靶点。
Int J Mol Sci. 2022 Aug 5;23(15):8702. doi: 10.3390/ijms23158702.
9
Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses' Health Studies.PTEN 表达缺失、PIK3CA 突变与护士健康研究中的乳腺癌生存
Cancer Epidemiol Biomarkers Prev. 2022 Oct 4;31(10):1926-1934. doi: 10.1158/1055-9965.EPI-22-0672.
10
Prognostic value of an immunohistochemical signature in patients with pulmonary squamous cell carcinoma undergoing complete surgical resection.免疫组化特征对接受根治性手术切除的肺鳞状细胞癌患者的预后价值。
J Thorac Dis. 2022 Feb;14(2):536-545. doi: 10.21037/jtd-22-118.

本文引用的文献

1
New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer.三阴性乳腺癌患者中Ki-67标记指数预后价值的新见解。
Oncotarget. 2016 Apr 26;7(17):24824-31. doi: 10.18632/oncotarget.8531.
2
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.程序性死亡配体1在三阴性乳腺癌中的表达与肿瘤浸润淋巴细胞及预后改善相关。
Histopathology. 2016 Jul;69(1):25-34. doi: 10.1111/his.12904. Epub 2016 Jan 13.
3
High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.在870例中国乳腺癌患者中,程序性死亡受体配体1(PD-L1)高表达与预后不良相关。
Oncotarget. 2015 Oct 20;6(32):33972-81. doi: 10.18632/oncotarget.5583.
4
Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.对6000多名乳腺癌患者的预测性生物标志物分析显示三阴性乳腺癌存在异质性,并对治疗有影响。
Clin Breast Cancer. 2015 Dec;15(6):473-481.e3. doi: 10.1016/j.clbc.2015.04.008. Epub 2015 Apr 28.
5
Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases.c-Met在乳腺癌中的预后意义:对6010例病例的荟萃分析
Diagn Pathol. 2015 Jun 6;10:62. doi: 10.1186/s13000-015-0296-y.
6
p63 Sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling.p63通过调控音猬因子信号通路维持乳腺癌干细胞的自我更新。
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3499-504. doi: 10.1073/pnas.1500762112. Epub 2015 Mar 4.
7
BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.BCL2是接受基于蒽环类药物辅助化疗的基底样三阴性乳腺癌预后的独立预测指标。
Tumour Biol. 2015 Jun;36(6):4243-52. doi: 10.1007/s13277-015-3061-7. Epub 2015 Jan 24.
8
Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancer.Ki67作为三阴性乳腺癌患者预后不良的预测指标。
Oncol Lett. 2015 Jan;9(1):149-152. doi: 10.3892/ol.2014.2618. Epub 2014 Oct 15.
9
Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.新辅助化疗前后Ki67表达在HR阴性乳腺癌中的预后价值
Int J Clin Exp Pathol. 2014 Sep 15;7(10):6862-70. eCollection 2014.
10
C-kit and PDGFRA gene mutations in triple negative breast cancer.三阴性乳腺癌中的C-kit和血小板衍生生长因子受体A(PDGFRA)基因突变
Int J Clin Exp Pathol. 2014 Jun 15;7(7):4280-5. eCollection 2014.

Claudin-7、程序性死亡受体1(PDL-1)、第10号染色体缺失的磷酸酶及张力蛋白同源物(PTEN)、原癌基因c-Kit、肝细胞生长因子受体(c-Met)、原癌基因c-Myc、间变性淋巴瘤激酶(ALK)、细胞角蛋白5/6(CK5/6)、细胞角蛋白17(CK17)、抑癌基因p53、表皮生长因子受体(EGFR)、细胞增殖相关核抗原(Ki67)、抑癌基因p63在三阴性乳腺癌中的表达及临床意义——一项单中心前瞻性观察性研究

Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study.

作者信息

Constantinou Chloe, Papadopoulos Savvas, Karyda Eirini, Alexopoulos Athanasios, Agnanti Niki, Batistatou Anna, Harisis Haris

机构信息

Breast Unit, Royal Free Hospital, London, U.K.

Breast Unit, Hygeia Hospital, Athens, Greece.

出版信息

In Vivo. 2018 Mar-Apr;32(2):303-311. doi: 10.21873/invivo.11238.

DOI:10.21873/invivo.11238
PMID:29475913
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5905198/
Abstract

BACKGROUND/AIM: To explore the relationship between p53, p63, c-kit, Ki67, cMet, claudin7, CK5/6, CK17, AR, PTEN, EGFR, ALK, PDL-1 and c-MYC expression with the clinicopathological features of triple- negative breast cancer.

MATERIALS AND METHODS

Immunohistochemistry was performed in 84 triple-negative breast cancer samples.

RESULTS

A statistically significant relationship between tumour grade and claudin-7 (p=0.004) and between protein p53 and positive lymph nodes (p=0.015) was found. High expression of claudin-7 (OR=65.8, 95%CI=4.35-995.19, p-value=0.003) and low expression of c-kit (OR=0.14, 95%CI=0.025-0.793, p-value=0.026) and protein p63 (OR=0.18 95%CI=0.035-0.978, p-value=0.047) was associated with higher tumour grade. Higher AR expression (OR=13.44, 95%CI=1.28-141.56, p-value=0.031) and lower expression of CK5/6 cytokeratins was found in patients with positive lymphovascular invasion (LVI) (OR=0.072, 95%CI=0.007-0.732, p-value=0.026). Only the cell proliferation index (Ki67) has been proven to be statistically significant for disease-free survival (p-value=0.0378), and overall survival (p-value=0.0186).

CONCLUSION

High expression of claudin-7 and low expression of c-kit and protein p63 are associated with higher tumour grade. AR and CK5/6 expression seem to be important in LVI.

摘要

背景/目的:探讨p53、p63、c-kit、Ki67、cMet、claudin7、CK5/6、CK17、AR、PTEN、EGFR、ALK、PDL-1和c-MYC的表达与三阴性乳腺癌临床病理特征之间的关系。

材料与方法

对84例三阴性乳腺癌样本进行免疫组织化学检测。

结果

发现肿瘤分级与claudin-7之间存在统计学显著关系(p=0.004),蛋白质p53与阳性淋巴结之间存在统计学显著关系(p=0.015)。claudin-7高表达(OR=65.8,95%CI=4.35-995.19,p值=0.003)、c-kit低表达(OR=0.14,95%CI=0.025-0.793,p值=0.026)和蛋白质p63低表达(OR=0.18,95%CI=0.035-0.978,p值=0.047)与更高的肿瘤分级相关。在有阳性淋巴管浸润(LVI)的患者中发现更高的AR表达(OR=13.44,95%CI=1.28-141.56,p值=0.031)和更低的CK5/6细胞角蛋白表达(OR=0.072,95%CI=0.007-0.732,p值=0.026)。只有细胞增殖指数(Ki67)被证明对无病生存期(p值=0.0378)和总生存期(p值=0.0186)具有统计学意义。

结论

claudin-7高表达、c-kit和蛋白质p63低表达与更高的肿瘤分级相关。AR和CK5/6表达似乎在淋巴管浸润中起重要作用。